ArticleChinese medicine2026
Narcissoside attenuates atherosclerosis by suppressing CD36-mediated foam cell formation via upregulation of NR4A1.
Article in Chinese medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe formation of foam cells (FCs) is the major contributor to the development of atherosclerosis (AS). Gynostemma pentaphyllum is widely used to treat AS and exhibits biological activity against FCs formation. Narcissoside (Nar) is an important component from G. pentaphyllum flavonoids. This study aimed to reveal the beneficial effect and underlying mechanism of Nar on inhibiting the formation of FCs in AS.
methodsThe inhibitory effects of Nar on FCs formation were evaluated using Oil Red O staining and flow cytometry in ox-LDL-stimulated THP-1 and BMDMs. High-fat diet (HFD)-induced ApoE
resultsIn vitro, Nar attenuated FCs formation as evidenced by reduced intracellular lipid levels and ox-LDL uptake rates. In vivo, Nar effectively improved lipid profiles and serum inflammatory factors. Histological analysis showed that Nar reduced the area of the necrotic core and lipid accumulation in the aortic roots. Mechanistically, Nar inhibited CD36 transcription by enhancing the expression and nuclear translocation of NR4A1. Mutation of the NR4A1 binding site within the CD36 promoter abolished the inhibitory effect of Nar. Additionally, silencing NR4A1 eliminated Nar's capacity to suppress ox-LDL uptake and downregulate CD36 expression.
conclusionsNar attenuated AS by inhibiting CD36-mediated FCs formation through upregulating the expression and nuclear translocation of NR4A1, highlighting it as a promising therapeutic candidate for AS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.